REG - Creo Medical Group - Award of Shares under SIP and Director Dealings

Creo MedicalAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250724:nRSX3264Sa&default-theme=true

RNS Number : 3264S  Creo Medical Group PLC  24 July 2025

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Award of Shares under Share Incentive Plan and Director Dealings

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP")
during 2020, which is available to all of the Company's UK based employees,
including Directors.

 

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"),
the independent trustee of the SIP, acquired, in accordance with the SIP's
rules and on behalf of SIP participants, 228,940 ordinary shares in the
Company ("Ordinary Shares"), at a price of £0.14 per Ordinary Share on 22
July 2025 to meet its obligations under the SIP (the "Partnership Shares").
Under the terms of the SIP, the Company is required to issue or make available
to the SIP two Ordinary Shares in the Company for each Partnership Share
purchased (being 457,880 Ordinary Shares in total for the six-month period to
end of June 2025, the "Matching Shares"). Fiduchi currently holds 2,664,126
unallocated Ordinary Shares within the SIP which can be utilised to satisfy
the Company's obligation to issue or make available Matching Shares.
Accordingly, 457,880 Ordinary Shares will be utilised by Fiduchi as trustee of
the SIP to meet this matching obligation, and no new Ordinary Shares are
required to be issued to satisfy the Company's obligations under the SIP.

 

Craig Gulliford and Richard Rees, executive directors of the Company (the
"Participating Directors"), have acquired Partnership Shares at a price of
£0.14 per share and received Matching Shares at a price of £0.001 per share
in accordance with terms of the SIP (the "Transaction"). Following the
Transaction, the Participating Directors' shareholdings in the Company are as
set out in the table below:

 

 Director              Total number of Ordinary Shares purchased or awarded under SIP  Total number of Ordinary Shares held post Transaction
 Craig Gulliford, CEO  19,287                                                          1,686,194(1)
 Richard Rees, CFO     19,287                                                          3,069,963(2)

 

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail in relation to the award of
the SIP Shares to the Participating Directors.

 

Notes:

(1) Includes shares held by Mr Gulliford's wife.

(2) Includes shares held by Mr Rees's wife and PCAs.

 

For further information please contact:

 

 Creo Medical Group plc                                                      www.creomedical.com
                                                                             (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                           Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Broker and Financial Adviser)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Sher Shah

 Walbrook PR Ltd                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings      Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 1. Details of PDMR
 a)  Name                                     Craig Gulliford
 b)  Position / status                        CEO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Purchase of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices  Volume(s)
                                              £0.14   6,429
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-07-22 BST

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-07-22 BST

f)

Place of the transaction

London Stock Exchange

 

 

 

 1. Details of PDMR
 a)  Name                                     Craig Gulliford
 b)  Position / status                        CEO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Award of Ordinary Shares (Matching Shares) under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.001   12,858
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-07-22 BST

     transaction
 f)  Place of the transaction                 Off-market

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-07-22 BST

f)

Place of the transaction

Off-market

 

 

 1. Details of PDMR
 a)  Name                                     Richard Rees
 b)  Position / status                        CFO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Purchase of Ordinary Shares under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices  Volume(s)
                                              £0.14   6,429
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-07-22 BST

     transaction
 f)  Place of the transaction                 London Stock Exchange

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-07-22 BST

f)

Place of the transaction

London Stock Exchange

 

 

 

 1. Details of PDMR
 a)  Name                                     Richard Rees
 b)  Position / status                        CFO
 c)  Initial notification / amendment         Initial notification
 2. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Nature of the transaction                Award of Ordinary Shares (Matching Shares) under Share Incentive Plan

 c)  Price(s) and volume(s)                   Prices   Volume(s)
                                              £0.001   12,858
 d)  Aggregated information                   N/A - Single transaction

     Aggregated volume Price
 e)  Date of the                              2025-07-22 BST

     transaction
 f)  Place of the transaction                 Off-market

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2025-07-22 BST

f)

Place of the transaction

Off-market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDDGDRDGDDGUX